More than one-third of patients achieved major pathologic response with nivolumab-ipilimumab.
Large proportion of intermediate- to high-risk patients could avoid aggressive therapy
Co-existence tied to severe disease, organ failure, and longer hospital stays
No significant difference in days without delirium or coma
ASCO guideline covers patient selection, treatment options, follow-up
Major response rate of 21%, encouraging survival with single-agent atezolizumab
Studies: fewer diagnoses, more severe disease, worse outcomes, distressed patients
News, features, and commentary about cancer-related issues
Enlarged spaces around cerebral small blood vessels linked to cognitive decline over time
International registry shows older age, comorbidities are risks; anti-TNF might protect